Biologically Active Peptides
AG30/5C
Code

Compound4469-s

AG30/5C
Met-Leu-Lys-Leu-Ile-Phe-Leu-His-Arg-LeuLys-Arg-Met-Arg-Lys-Arg-Leu-Lys-Arg-LysLeu-Arg-Leu-Trp-His-Arg-Lys-Arg-Tyr-Lys

New

-20

(M.W. 4103.2)

Price:Yen
Vial

0.1 mg10,000C189H330N66O32S2

Antimicrobial Peptide with Angiogenic Properties
Peptides with antimicrobial activity, in addition to angiogenic properties are good candidates forwound-healing drugs. One such peptide lead, AG30 (AG: Angiogenic Peptide) was identified in 2009 by thegroup of Drs. Nakagami and Kaneda of Osaka University1). Actually, AG30 is predicted by in silico analysis ofan angiogenic cDNA clone p37432).
Through feasibility study and the subsequent clinical investigation of AG30, AG30/5C has just been
discovered from the structure-activity relationship study of AG30. In AG30/5C the cationic residues of Arg andLys replace five neutral amino acids3). This modification in the primary structure revealed that i) the helicalstructure is maintained even in the lower extent than that of parental AG30, ii) the potencies are significantly
improved in the migration and tube forming ability of human endothelial cells as well as in the antimicrobialactivity against P. aeruginosa, Candida, and S. aureus, and iii) wound healing effects are observed in a diabetic
mouse model and in a porcine model (100 µg/ml).
In this study, AG30/5C is produced applying the conventional solution method compatible to Good
Manufacturing Practice (GMP) guidelines. The structure and characteristics of AG30/5C are similar to those of
LL-37, which is known as an antimicrobial peptide with angiogenic properties. AG30/5C, which may facilitate
the discovery of novel therapeutic agents, is available now from Peptide Institute, Inc.
AG30:
AG30/5C:MLSLIFLHRLKSMRKRLDRKLRLWHRKNYPMLKLIFLHRLKRMRKRLKRKLRLWHRKRYK

1) T. Nishikawa, H. Nakagami, A. Maeda, R. Morishita, N. Miyazaki, T. Ogawa, Y. Tabata, Y. Kikuchi, H. Hayashi,
Y. Tatsu, N. Yumoto, K. Tamai, K. Tomono, and Y. Kaneda, J. Cell. Mol. Med., 13, 535 (2009).
(Original; AG30 & Pharmacol.)2) T. Nishikawa, H. Nakagami, A. Matsuki, A. Maeda, C.Y. Yo, T. Harada, R. Morishita, K. Tamai, and Y. Kaneda,
Hum. Gene Ther., 17, 470 (2006). (Angiogenic cDNA Clone p3743)
3) H. Nakagami, T. Nishikawa, N. Tamura, A. Maeda, H. Hibino, M. Mochizuki, T. Shimosato, T. Moriya, R. Morishita,
K. Tamai, K. Tomono, and Y. Kaneda, J. Cell. Mol. Med., doi: 10.1111/j.1582-4934.2011.01406.x(Original; AG30/5C & Pharmacol.)• This product is distributed through Peptide Institute, Inc. under the license of AnGes MG, Inc. Its use for any purpose
other than research is strictly prohibited.

–1 –AMP-IBP5
CodeCompoundPrice:Yen

4468-sAMP-IBP5 (Human)
Vial
0.1 mgInsulin-Like Growth Factor-Binding Protein 5 (Human, 193-214 Amide)(Porcine, Rat, Mouse, Bovine)
Ala-Val-Tyr-Leu-Pro-Asn-Cys-Asp-Arg-LysGly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-ProSer-Arg-NH2

10,000New-20

(Disulfide bond between Cys7-Cys18)(M.W. 2655.1)

C117H188N38O29S2

Antimicrobial Peptide
Dr. Minamino and his colleagues of National Cerebral and Cardiovascular Center Research Institute havebeen performing the proteomics approach to unveil the endogenous peptides. His group has now
identified a novel antimicrobial peptide, AMP-IBP5 [named after an antimicrobial peptide derived frominsulin-like growth factor-binding protein 5 (IGFBP-5)] using human pancreatic neuroendocrine tumor cell
QGP-11).
AMP-IBP5 is actually a 22 amino acid residue peptide with dual post-translational modifications: C-terminal
amidation and intramolecular disulfide bond formation, the latter of which is a distinct finding because thedisulfide linkage of IGFBP-5 has been differently predicted previously. The primary structure of AMP-IBP5 isconserved among many mammals including human, mouse, rat, pig, and cow. AMP-IBP5 is characterized tohave a highly basic nature and exerts broad spectra of antimicrobial activity against Gram-positive bacteria,
Gram-negative bacteria, and fungi (IC50 = µM range), the potency of which were comparable to LL-37 (Code4445-s) and even higher than those of human β-defensin-2 (Code 4338-s). Interestingly, this function is missingin parental IGFBP-5. Major location sites of immunoreactive AMP-IBP5 in rats are clarified as being thepituitary gland, brain, and small intestine.
This newly discovered AMP-IBP5 has the potential to become an essential peptide with antimicrobialactivity, along with existing antimicrobial peptides such as defensins and LL-37.
1) T. Osaki, K. Sasaki, and N. Minamino, J. Proteome Res., 10, 1870 (2011). (Original; Primary Structure & Pharmacol.)–2 –Ternatin
Code

CompoundPrice:Yen

4464-v

New[D-Leu7]-(-)-Ternatin
cyclo(-D-aIle-MeAla-MeLeu-Leu-MeAla-D-MeAla-D-Leu-)-20

(M.W. 721.97)

Vial

1 mg

30,000C37H67N7O7

Fat Accumulation Inhibitor against 3T3-L1 Adipocytes
Professor Uemura of Nagoya University isolated (-)-ternatin from the mushroom Coriolus versicolor anddetermined its structure by the combination of NMR analysis and total chemical synthesis1). The inhibitory
effects of this highly N-methylated cyclic 7-peptide, (-)-ternatin, in both adipogenesis and lipid metabolism,
have been clarified in vitro as well as in vivo2,3). These include: i) a fat accumulation inhibitory effect and cell
viability in 3T3-L1 murine adipocytes (IC50 = 0.027 µM and 0.28 µM, respectively) and ii) suppression of bodyweight gain and fat accumulation in C57BL/6J mice at a dose of 5 mg/kg/day, together with iii) mechanism forexerting these inhibitory activity.
Later, his group found [D-Leu7]-(-)-ternatin as a useful derivative of (-)-ternatin during a structure-activity
relationship study. Actually, this peptide, a deletion analog of β-OH group from the 7th amino acid, β-OHD-Leu, maintains not only fat accumulation inhibitory activity with only an 8-fold-lower potency, but also thestructural integrity of the parent molecule4,5). This specific analog, [D-Leu7]-(-)-ternatin, may be an alternativeto (-)-ternatin in the study to combat metabolic diseases in the modern world. [D-Leu7]-(-)-Ternatin is now
available from Peptide Institute, Inc. under an agreement with Professor Uemura.
1) K. Shimokawa, I. Mashima, A. Asai, K. Yamada, M. Kita, and D. Uemura, Tetrahedron Lett., 47, 4445 (2006).
((-)-Ternatin; Structure Determination / Biological Activity in vitro)
2) K. Shimokawa, K. Yamada, M. Kita, and D. Uemura, Bioorg. Med. Chem. Lett., 17, 4447 (2007).
((-)-Ternatin; Biological Activity in vivo)
3) M. Ito, J. Ito, H. Kitazawa, K. Shimamura, T. Fukami, S. Tokita, K. Shimokawa, K. Yamada, A. Kanatani,and D. Uemura, Peptides, 30, 1074 (2009). ((-)-Ternatin; Mechanism of Inhibitory Activity)4) K. Shimokawa, Y. Iwase, K. Yamada, and D. Uemura, Org. Biomol. Chem., 6, 58 (2008).
(D-Leu7-(-)-Ternatin; Biological Activity in vivo)
5) K. Shimokawa, R. Miwa, K. Yamada, and D. Uemura, Org. Biomol. Chem., 7, 777 (2009).
(D-Leu7-(-)-Ternatin; Conformation-Biological Activity Relationship)• This compound is distributed through Peptide Institute, Inc. under the license of Nagoya University.

–3 –Hepcidin
CodeCompound4467-v

Hepcidin (Rat)
Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-CysCys-Lys-Cys-Cys-Lys-Asn-Ser-Ser-Cys-GlyLeu-Cys-Cys-Ile-Thr

New

-20

Price:Yen
Vial

50 µg

28,000(Disulfide bonds undetermined)(M.W. 2712.2)

C111H171N29O34S8

Iron-Regulatory Hormone
1) C. Pigeon, G. Ilyin, B. Courselaud, P. Leroyer, B. Turlin, P. Brissot, and O. Loréal, J. Biol. Chem., 276, 7811 (2001).
(Primary Structure: GenBank Accession No. AF344185)

Peptide Tools
3405-v

New[13C18,15N3]-Hepcidin (Human)[[13C9,15N]Phe4,9, [15N]Gly12]-Hepcidin (Human)-20

(Trifluoroacetate Form)

Vial

20 µg

20,000

Asp-Thr-His-[13C9,15N]Phe-Pro-Ile-Cys-Ile-[13C9,15N]Phe-CysCys-[15N]Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-GlyMet-Cys-Cys-Lys-Thr(Reported disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22)(M.W. 2810.2)

C9513C18H170N3115N3O31S9

Stable Isotope-Labeled Peptide for Mass Spectrometric Detection of Hepcidin (Human)
1) N. Murao, M. Ishigai, H. Yasuno, Y. Shimonaka, and Y. Aso, Rapid Commun. Mass Spectrom., 21, 4033 (2007).
2) T. Hosoki, K. Ikuta, Y. Shimonaka, Y. Sasaki, H. Yasuno, K. Sato, T. Ohtake, K. Sasaki, Y. Torimoto, K. Saito,
and Y. Kohgo, Proteomics Clin. Appl., 3, 1256 (2009).
本製品に関連して、ペプチドの定量方法に関する特許出願（日本再公表2008/093762）が存在します。
ご興味のある方は中外製薬株式会社知的財産部（電話番号0467-47-2362）までご連絡ください。

3404-v

New

4-[D10]Leu-Insulin (Human)[[2H10]LeuB6,B11,B15,B17]-Insulin (Human)-20

(Trifluoroacetate Form)

Vial

20 µg

20,000A-chain:
Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-IleCys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-CysAsn
B-chain:
Phe-Val-Asn-Gln-His-[2H10]Leu-Cys-Gly-Ser-His[2H10]Leu-Val-Glu-Ala-[2H10]Leu-Tyr-[2H10]Leu-Val-Cys-GlyGlu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr(Disulfide bonds between CysA6-CysA11, CysA7-CysB7, and CysA20-CysB19)(M.W. 5847.8)

C257H343D40N65O77S6

Stable Isotope-Labeled Peptide Useful for Standardization of Insulin Immunoassays
1) K. Van Uytfanghe, D. Rodr́guez-Cabaleiro, D. Stockl, and L.M. Thienpont, Rapid Commun. Mass Spectrom., 21,
819 (2007).
2) D. Rodr́guez-Cabaleiro, K. Van Uytfanghe, V. Stove, T. Fiers, and L.M. Thienpont, Clin. Chem., 53, 1462 (2007).
3) W.G. Miller, L.M. Thienpont, K. Van Uytfanghe, P.M. Clark, P. Lindstedt, G. Nilsson, and M.W. Steffes,
Clin. Chem., 55, 1011 (2009).

–4 –Peptide Tools (continued)
Code

CompoundPrice:Yen

3403-v

New

Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu
Vial
0.5 mgMyristoyl-PKCζ (113-125) / ζ-Pseudosubstrate Inhibitory Peptide (ZIP)10,000-20

(Trifluoroacetate Form)

Myristoyl-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-TrpArg-Lys-Leu(M.W. 1928.4)

C90H154N30O17

Myristoylated Cell Permeable PKC ζ Pseudosubstrate Inhibitor
1) C. Laudanna, D. Mochly-Rosen, T. Liron, G. Constantin, and E.C. Butcher, J. Biol. Chem., 273, 30306 (1998).
(Pharmacol.)2) S. Lim, J.W. Choi, H.S. Kim, Y.-H. Kim, K. Yea, K. Heo, J.H. Kim, S.-H. Kim, M. Song, J.I. Kim, S.H. Ryu,
and P.-G. Suh, Life Sci., 82, 733 (2008). (Biochem.)
3) T. Hirose, D. Satoh, H. Kurihara, C. Kusaka, H. Hirose, K. Akimoto, T. Matsusaka, I. Ichikawa, T. Noda,
and S. Ohno, PLoS ONE, 4, e4194 (2009). (Pharmacol. & Histochem.)
4) P.V. Migues, O. Hardt, D.C. Wu, K. Gamache, T.C. Sacktor, Y.T. Wang, and K. Nader,Nat. Neurosci., 13, 630 (2010). (Pharmacol.)Carbohydrate
23004-sNew-20

GnGn-bi-Asn-PABA
Vial
0.1 mg28,000Semisynthetic Product with Enzymatically Derived Bovine γ-Globulin Sugar Moiety
O-β-2-Acetamido-2-deoxy-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)[O-β-2-acetamido-2-deoxy-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→6)]O-β-D-mannopyranosyl-(1→4)-O-β-2-acetamido-2-deoxy-D-glucopyranosyl-(1→4)-Nβ-2-acetamido-2-deoxy-D-glucopyranosyl-(1→4)-L-asparagine 4-(2-pyridylamino)
butylamide
OH
O

HO

O

HO
AcNH
OH

O
HO
HO
O

OH
OH

OH

O
HO
O

O

O

HO
HO

AcNH

HO

O
O
HO

H
N

AcNH

NH
HN
H2N

OH

OH

N

O

O
O

HO

(M.W. 1578.5)

C63H103N9O37

O
O

HO
AcNH

Semisynthetic Product

Substrate for GDP-L-Fuc: N-Acetyl-β -D-Glucosaminide α 1-6Fucosyltransferase
1) N. Uozumi, T. Teshima, T. Yamamoto, A. Nishikawa, Y.-E Gao, E. Miyoshi, C.-X. Gao, K. Noda, K.N. Islam, Y. Ihara,
S. Fujii, T. Shiba, and N. Taniguchi, J. Biochem., 120, 385 (1996). (Original; Semisynthesis & Assay Method)2) K. Noda, E. Miyoshi, J. Gu, C.-X. Gao, S. Nakahara, T. Kitada, K. Honke, K. Suzuki, H. Yoshihara, K. Yoshikawa,
K. Kawano, M. Tonetti, A. Kasahara, M. Hori, N. Hayashi, and N. Taniguchi, Cancer Res., 63, 6282 (2003).
(GDP-L-fucose Levels in Human Hepatocellular Carcinoma)3) Y. Shimma, F. Saito, F. Oosawa, and Y. Jigami, Appl. Environ. Microbiol. 72, 7003 (2006).
(Construction of a Library of Human Glycosyltransferases)
4) K. Matsumoto, H. Yokote, T. Arao, M. Maegawa, K. Tanaka, Y. Fujita C. Shimizu, T. Hanafusa, Y. Fujiwara,
and K. Nishio, Cancer Sci. 99, 1611 (2008). (Effect of Fucosylation on Epidermal Growth Factor Receptor Activity)–5 –Enzyme Substrates
Code

CompoundPrice:Yen

3230-vNew

Abz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-EDDnp[Abz-APEEIMRRQ-EDDnp]-20

(Trifluoroacetate Form)

Vial

1 mg

10,0002-Aminobenzoyl-L-alanyl-L-prolyl-L-glutamyl-L-glutamyl-L-isoleucylL-methionyl-L-arginyl-L-arginyl-L-glutamine 2-(2,4-dinitrophenyl)aminoethylamide(M.W. 1456.59)

C61H93N21O19S

Fluorescence-Quenching Substrate for Human Neutrophil Elastase
1) B. Korkmaz, S. Attucci, T. Moreau, E. Godat, L. Juliano, and F. Gauthier, Am. J. Respir. Cell Mol. Biol., 30, 801(2004).
2) B. Korkmaz, S. Attucci, M.A. Juliano, T. Kalupov, M.-L. Jourdan, L. Juliano, and F. Gauthier, Nat. Protoc., 3, 991(2008).

3231-vNew

Abz-Glu-Pro-Phe-Trp-Glu-Asp-Gln-EDDnp[Abz-EPFWEDQ-EDDnp]-20

(Ammonium Form)

Vial

1 mg

10,0002-Aminobenzoyl-L-glutamyl-L-prolyl-L-phenylalanyl-L-tryptophylL-glutamyl-L-aspartyl- L-glutamine 2-(2,4-dinitrophenyl)aminoethyl-amide(M.W. 1277.25)

C59H68N14O19

Fluorescence-Quenching Substrate for Human Neutrophil Cathepsin G1) S. Attucci, B. Korkmaz, L. Juliano, E. Hazouard, C. Girardin, M. Brillard-Bourdet, S. Réhault, P. Anthonioz,
and F. Gauthier, Biochem. J., 366, 965 (2002).
2) B. Korkmaz, S. Attucci, M.A. Juliano, T. Kalupov, M.-L. Jourdan, L. Juliano, and F. Gauthier, Nat. Protoc., 3, 991(2008).

3232-vNew

Abz-Val-Ala-Asp-Nva-Arg-Asp-Arg-Gln-EDDnp[Abz-VADnVRDRQ-EDDnp], nV = Nva-20

(Trifluoroacetate Form)

Vial

1 mg

10,0002-Aminobenzoyl-L-valyl-L-alanyl-L-aspartyl-L-norvalyl-L-arginylL-aspartyl-L-arginyl- L-glutamine 2-(2,4-dinitrophenyl)aminoethyl-amide(M.W. 1285.3)

C53H80N20O18

Fluorescence-Quenching Substrate for Human Neutrophil Proteinase 31) B. Korkmaz, E. Hajjar, T. Kalupov, N. Reuter, M. Brillard-Bourdet, T. Moreau, L. Juliano, and F. Gauthier,J. Biol. Chem., 282, 1989 (2007).
2) B. Korkmaz, S. Attucci, M.A. Juliano, T. Kalupov, M.-L. Jourdan, L. Juliano, and F. Gauthier, Nat. Protoc., 3, 991(2008).

–6 –Products of Peptides International, Inc.
R○****** Amino Acid Derivatives (dPEG ) ******Code
DPG-5748-PI

New

2～10

CompoundPrice:YenR○

N-Fmoc-Amido-dPEG 2 Acid

1g
5g



10.9 A and 10 Atoms Spacer

35,000140,000(M.W. 399.44)
O

O
O

O

N
H

O

OH

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5749-PI

New

2～10

N-Fmoc-Amido-dPEG○R 4 Acid

18.1 A and 16 Atoms Spacer

100 mg1g

20,00055,000100 mg1g

25,00080,000100 mg1g

30,000120,000

100 mg1g

30,000140,000

100 mg1g

50,000250,000

100 mg1g

20,00055,000(M.W. 487.54)

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5750-PI

New

2～10

N-Fmoc-Amido-dPEG○R 6 Acid

25.1 A and 22 Atoms Spacer(M.W. 575.65)

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5751-PI

New

2～10

N-Fmoc-Amido-dPEG○R 8 Acid

32.2 A and 28 Atoms Spacer(M.W. 663.75)

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5752-PI

New

2～10

N-Fmoc-Amido-dPEG○R 12 Acid

46.5 A and 40 Atoms Spacer(M.W. 839.96)

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5753-PI

New

2～10

N-Fmoc-Amido-dPEG○R 24 Acid


89 A and 76 Atoms Spacer(M.W. 1368.59)

N–Fmoc Protected Hydrophilic, Non–Immunogenic Spacer
DPG-5759-PI

New

2～10

N-Boc-Amido-dPEG○R 4 Acid

19.2 A and 16 Atoms Spacer(M.W. 365.42)
O

O
O

O

N
H

O
O

N–Boc Protected Hydrophilic, Non–Immunogenic Spacer
dPEG is a proprietary product of Quanta BioDesign, Ltd.

–7 –

O

OH

Products of Peptides International, Inc. (continued)****** Reagents for Click Chemistry ******
Code

Compound

PRA-5010-PI

Fmoc-Pra-OH

2～10

9-Fluorenylmethoxycarbonyl-Propargyl-L-Glycine(S)-2-(Fmoc-amino)-4-Pentynoic acidNew

(M.W. 335.36)

Price:Yen
1g

35,000

C20H17NO4
O
OH
O

N
H
O

Alkyne Building Block for Click Chemistry1) M. Meldal, M.A. Juliano, and A.M. Jansson, Tetrahedron Lett., 38, 2531 (1997).
2) S. Punna, J. Kuzelka, Q. Wang, and M.G. Finn, Angew. Chem. Int. Ed., 44, 2215 (2005).

FAK-1903-PI

New

2～10

1g

Fmoc-Azido-Lys-OH
Fmoc-Lys(N3)-OH

94,000N3Nα-9-Fluorenylmethoxycarbonyl-ε-Azido-L-Lysine(M.W.394.43)

C21H22N4O4[159610-89-6]
O
OH
O

N
H
O

Azido Building Block for Click Chemistry1) A. Le Chevalier Isaad, A.M. Papini, M. Chorev, and P. Roveroa, J. Pept. Sci., 15, 451 (2009).
2) P.E. Schneggenburger, B. Worbs, and U. Diederichsen, J. Pept. Sci., 16, 10 (2010).

AHA-1904-PI

New

6-Azido-Hexanoic Acidε–Azidocaproic Acid

2～10

(M.W. 157.17)

1g

36,000OH

C6H11N3O2[79598-53-1]

N3
O

Azido Building Block for Click Chemistry1) P. Wu, A.K. Feldman, A.K. Nugent, C.J. Hawker, A. Scheel, B. Voit, J. Pyun, J.M.J. Fréchet, K.B. Sharpless, and
V.V. Fokin, Angew. Chem. Int. Ed., 43, 3928 (2004).
2) C. Grandjean, A. Boutonnier, C. Guerreiro, J.-M. Fournier, and L.A. Mulard, J. Org. Chem., 70, 7123 (2005).
3) A. Watzke, M. Gutierrez–Rodriguez, M. Kohn, R. Wacker, H. Schroeder, R. Breinbauer, J. Kuhlmann,
K. Alexandrov, C.M. Niemeyer, R.S. Goody, H. Waldmann, Bioorg. Med. Chem., 14, 6288 (2006).

APA-1906-PI

New

5-Azido-Pentanoic Acid
δ-Azidovaleric Acid

2～10

(M.W. 143.15)

C5H9N3O2

1g

36,000[79583-98-5]

Azido Building Block for Click Chemistry1) M. Meldal, M.A. Juliano, and A.M. Jansson, Tetrahedron Lett., 38, 2531 (1997).
2) S. Punna, J. Kuzelka, Q. Wang, and M.G. Finn, Angew. Chem. Int. Ed., 44, 2215 (2005).

AXX-1905-PI

8-Azido-3,6-Dioxaoctanoic Acid CHA Salt
Azido-mini-PEGTM cyclohexylamine

2～10(M.W. 189.17 • 99.18)

C6H11N3O4 • C6H13N

Azido Building Block for Click Chemistry

–8 –

1g

65,000笊

ご希望のペプチド（Cys 含有ペプチドも含む）
2-60 残基（60 残基を越える場合も可能です。ご相談下さい）

笆
笳
笘
笙
笞
笵
笨
笶
筐
筺

生理活性ペプチドとその誘導体
細胞膜透過性ペプチド
各種酵素基質（MCA, p NA, その他の蛍光，発色基質など）
消光性蛍光基質（Nma-Dnp，MOCAc-Dnp，Dabcyl-EDANS の組合せなど）
酵素阻害剤（アルデヒド，フルオロメチルケトン，クロロメチルケトン誘導体など）
ジスルフィド結合含有ペプチド（複数架橋を有する場合もご相談下さい）
環状ペプチドおよび枝分かれペプチド
鎖状および環状デプシペプチド
リン酸化ペプチド［Ser（PO3H2），Thr（PO3H2），Tyr（PO3H2）誘導体］
ホスホノペプチド［リン酸化ペプチドのカルバ型誘導体］［Ser（PO3H2），Thr（PO3H2），Tyr（PO3H2）に対応するホスファターゼ抵抗性誘導体］

笄筍

硫酸化ペプチド［Tyr（SO3H）］
アミノ基修飾誘導体（Acetyl 化，Succinyl 化，Biotinyl 化，Boc 化，Z 化，Dnp 化，Dns 化，Myristoyl 化など種々の修飾）笋筌筅

チオール基修飾誘導体（Farnesyl 化，Geranyl 化，Biotinyl 化など）
蛍光標識ペプチド（FITC 化、Dns 化、Nma 化など）
糖ペプチド［Asn（GlcNAc），Ser/Thr（GalNAc），Ser/Thr（Gal-GalNAc），Ser/Thr（GlcNAc），
Ser（Xyl），Thr（Man）含有ペプチドなど］

筵
筥
筴
筧
筰
筱
筬
筮

非天然アミノ酸含有ペプチド
ペプチド結合の修飾（還元型、スタチン型など）
アミノ酸誘導体 , 保護ペプチド
安定同位体ラベルアミノ酸含有ペプチド（13C，15N，2H など）
ペプチドアルコール
糖関連化合物
一般有機化合物
その他

受託合成量： 25mg（固相法標準量）〜 g、kg オーダーまで承ります。（お見積り依頼の際に、ご相談下さい）
納期： 固相法にて合成可能な通常のペプチド 25mg の場合：通常 2-4 週間
液相法などその他の方法で合成する場合はご相談させていただきます。

保 証 純 度： 通常、トリフルオロ酢酸塩でご提供いたします。
規格 （1）逆相 HPLC で検定：80-95%（精製品）（2）逆相 HPLC で検定：95% 以上（精製品）（3）逆相 HPLC で検定：99% 以上（精製品）
通常、HPLC チャート、アミノ酸分析結果、質量分析結果を添付いたします。
その他の分析項目につきましてはご相談させていただきます。
価格： 個別にお見積りいたしますので、FAX 用ペプチド合成依頼書、あるいは E-mail にてご相談下さい。

} 医薬品開発研究用カスタム合成
弊社は、医薬品製造業許可を取得しており、医薬品原薬および原薬中間体の製造が可能です。
GMP 対応、治験薬 GMP 対応など個別にご相談させていただきます。

9 

ペプチド合成依頼書（□見積依頼書

□発注）
年

月

日

ご依頼者
ご 住 所〒□□□-□□□□

勤 務 先

ご所属

フ リ ガ ナ

お 名 前L

--F A X

-

-

T

E

（内線）

E - m a i l
アミノ酸配列（アミノ酸配列は1文字表記、3文字表記どちらでも結構です）

N末端
1

C末端→
2

3

ペプチド量
純

4

5

6

7

8

9

□ 25 mg(標準量)

10

11

13

14

□ 50 mg □度 (逆相HPLC)□ 80%～95%(精製品)

ご用途

12

15

16

17

mg □

18

19

g □

20

kg

□ 95%以上保証(精製品)□ 抗原(抗体作製)用□ その他（コンジュゲーション・抗体作製）

お差し仕えなければご記入下さい。

コンジュゲーション □ 希望する □ 希望しない
希望結合部位□ N端

キャリアー蛋白質の種類 □ BSA
抗体作製(ウサギ)

□ C端□ その他()□ KLH □ OVA □ その他()

□ 希望する（羽）□ 希望しない

抗体アフィニティー精製 □ 希望する □ 希望しない担体への結合□ ペプチド □ その他(

抗体の標識

□ ビオチン標識)□ パーオキシダーゼ標識（過ヨウ素酸法）

備考 (ご要望事項など)

お願いお見積り依頼・ご発注は、アミノ酸配列確認のため、FAXやE-mailなどの文書でお願いいたします。

株式会社

ペプチド研究所〒567-0085 大阪府 茨木市 彩都 あさぎ 7-2-9
電話072-643-4343 (直通) FAX072-643-4422
E-mail: custom＠peptide.co.jp http://www.peptide.co.jp/– 10 –